Table 2 Histoclinical characteristics of patients that achieved histologic remission of EoE on PPI monotherapy during baseline, PPI monotherapy trial, and FED monotherapy trial
Characteristics | Baseline, all patients (n = 22) | PPI monotherapy, all patients (n = 22) | FED monotherapy, all patients (n = 22) | FED monotherapy, patients histologicly responsive to FED monotherapy (n = 13) |
|---|---|---|---|---|
Peak eos/hpf, median (IQR) | 47.5(26.25–83.75) | 2.5 (0–6) | 10 (2.25–30) | 6 (1–10) |
Symptoms, n (%) | ||||
 Dysphagia | 18 (81.82%) | 5 (22.73%) | 4 (18.18%) | 2 (15.38%) |
 Food Impaction | 3 (13.64%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Heartburn | 9 (40.91%) | 3 (13.64%) | 5 (22.73%) | 4 (30.77%) |
 Chest pain | 4 (18.18%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Vomiting | 2 (9.09%) | 1 (4.55%) | 0 (0%) | 0 (0%) |
 Abdominal pain | 3 (13.64%) | 1 (4.55%) | 0 (0%) | 0 (0%) |
 Regurgitation | 1 (4.55%) | 1 (4.55%) | 0 (0%) | 0 (0%) |
 Asymptomatic | 0 (0%) | 14 (63.64%) | 15 (68.18%) | 8 (61.54%) |